Transaction Valued at $122.5M Establishes 20,000-Liter US Biologics Drug Substance Manufacturing Platform, Covering Development through Commercial Supply TAIPEI, TAIWAN – Media OutReach Newswire – 2 July 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “Bora Group”; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. […]